Search

Filters
Clear All
  • 1
  • 20

Phase

  • 3
  • 8
  • 2
  • 2
  • 5
  • 21
  • 9

Found 21 Solid Tumor trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

M
Mateusz Opyrchal, MD, PhD
18 years - 100 years
All genders
Phase 1
Interventional
What is the purpose of this study?This is a first-in-human, Phase I, open-label, multicenter study designed to evaluate they, tolerability and preliminary efficacy of WTX-124, a conditionally-activated IL-2drug, when administered as monotherapy and in combination with pembrolizumab, for thewith advanced solid tumors. THIS STUDY IS ENROLLING BY INVITATION ONLY - …
B
Brian Weiss
1 years - 21 years
All genders
Interventional
What is the purpose of this study?This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as …
R
Rohan Maniar
18 years or above
All genders
Phase 1/2
Interventional
What is the purpose of this study?Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small …
B
Brian Weiss
12 months - 30 years
All genders
Phase 1/2
Interventional
What is the purpose of this study?This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits ofgavivint in treating patients with solid tumors that has come back (recurrent) or does notd to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help …
M
Mateusz Opyrchal, MD, PhD
18 years - 100 years
All genders
Phase 1/2
What is the purpose of this study?To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not …
K
Kyle William Jackson
1 years - 30 years
All genders
Phase 2
What is the purpose of this study?To establish the recommended phase II dose of a flavored preparation of orally administered irinotecan (VAL-413) when given in combination with temozolomide for five consecutive days. To characterize and compare the pharmacokinetic profiles of VAL-413 and conventional irinotecan given orally To evaluate the palatability …
S
Sandeep Batra, MD
1 year - 25 years
All genders
What is the purpose of this study?This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent …
C
Courtney Rowan, MD
1 years - 26 years
All genders
What is the purpose of this study?The goal of this study is to identify and validate response to therapy biomarkers for NIV respiratory support in children with ICCs. The central hypothesis is that response-to-therapy biomarkers can identify those most likely to benefit from intervention with NIV. The rationale is that …
K
Kathy Miller, MD
18 years - 100 years
All genders
Phase 1/2
What is the purpose of this study?This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.THIS …
M
Mateusz Opyrchal, MD, PhD
18 years - 100 years
All genders
Phase 1/2
What is the purpose of this study?Phase 1a Dose Escalation/Cohort Expansion BBO-10203 Monotherapy Primary: To evaluate the safety and tolerability of BBO-10203, an inhibitor of the PI3Kα:RAS interaction, in subjects with locally advanced unresectable or metastatic (ie, advanced) HER2-positive BC; HR-positive, HER2-negative BC; KRAS mutant NSCLC; and KRAS mutant CRC. Secondary: To evaluate …
1 - 10 of 21